Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions Approximately one in three women remain HPV positive after cervical procedures for precancerous lesions.Tens of thousands of women in the US each year are diagnosed with high-grade cervical...

Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...